AstraZeneca job cuts hit Södertälje hard
Anglo-Swedish pharmaceuticals giant AstraZeneca is closing its research facilities in Södertälje, south of Stockholm, as part of a major restructuring, resulting in the loss of more than 1,000 Swedish jobs.
Published: 02 Feb 2012 10:40 CET
Anglo-Swedish pharmaceuticals giant AstraZeneca is closing its research facilities in Södertälje, south of Stockholm, as part of a major restructuring, resulting in the loss of around 1,000 Swedish jobs.
“It might be redundancies, it might be early retirements or jobs elsewhere in the company,” AstraZeneca spokesperson Ann-Leena Mikiver told the TT news agency.
On Thursday, the company said it would axe 7,300 jobs worldwide by 2014 in a new cost-cutting drive, despite delivering bumper annual profits.
The company's Södertälje workforce will be reduced by between 1,100 and 1,200 workers.
"Today the company announces the start of a new set of restructuring initiatives to further reduce costs and increase flexibility in all functional areas," the London-listed group said in a results statement.
It added: "The total number of positions expected to be impacted for this phase is estimated to be approximately 7,300."
Part of the restructuring calls for the closure of R&D activities in Södertälje and the creation of a “virtual” neuroscience team of around 40 to 50 scientists based in Boston in the United States and Cambridge in the UK.
However, AstraZeneca added that the new team would work closely with the Karolinska Institute in Stockholm and that Södertälje would remain “an important part of the AstraZeneca network” because it is the company’s largest manufacturing site and home base for business in the Scandinavian markets.
AstraZeneca's latest job cuts are forecast to deliver $1.6 billion in annual benefits by the end of 2014, and are part of an ongoing efficiency drive.
The company cut 12,600 positions between 2007 and 2009 and removed another 9,000 roles by the end of last year.
The group meanwhile revealed that earnings after taxation surged 23 percent to $9.98 billion last year, compared with $8.053 billion in 2010.
Revenues flattened to $8.66 billion, from $8.62 billion.
However, AstraZeneca warned that earnings were expected to fall this year as patents on key drugs expire and governments in Europe and the United States squeeze prices.
Your comments about this article:
The comments below have not been moderated in advance and are not produced by The Local unless clearly stated. Readers are responsible for the content of their own comments. Comments that breach our terms and conditions will be removed.
My heart, however, goes out to all the people losing their jobs. Hopefully a more ethical firm will take its place.
Many western governments are trying to cut the cost of their health services (including the drugs that are used in them), as well as getting more involved in legislation for drugs - which is costing the companies money.
Still, most European governments prefer companies who take on staff - rather than laying them off...
I am happy they leave Sweden - that`s for sure, not a very ethical company.
As there is nothing stopping these changes, I'm just curious what will happen in the coming decades when the economic centres of the world will consist of maybe 20 or so 40+ million mega cities. What will happen to Stockholm then? We have already seen it happen to Detroit in the US. Once a city larger than Stockholm where 2/3 or so of the population since the 60s has now left, and 25% in just the last decade.